Pre-existing low-frequency resistance mutations increase the risk of antiretroviral treatment failure in HIV-1 naïve patients  

作　　者：Yifan Su Rentian Cai Yinyin Zhu Mingli Zhong Mingxue Qi Chen Chen Zi Ye Hongying Zhang Hongxia Wei 

机构地区：[1]Department of Infectious Disease,The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine,Nanjing,Jiangsu 210023,China [2]Nanjing Center for Disease Control and Prevention Affiliated with Nanjing Medical University,Nanjing,Jiangsu 211103,China [3]Department of Epidemiology and Biostatistics,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China

出　　处：《Chinese Medical Journal》2023年第22期2756-2758,共3页中华医学杂志（英文版）

基　　金：supported by the 2020 Annual Medical Research Project of Jiangsu Commission of Health(No.ZDA 2020014);the Key Project supported by Medical Science and Technology Development Foundation,Nanjing Department of Health(Nos.ZKX 22040 and ZKX 19048)

摘　　要：To the Editor:High-frequency resistance(typically≥15-25%viral quasispecies)detected by conventional resistance assays has long been associated with failure of antiretroviral therapy(ART)to suppress viral replication,[1]but the impact of pre-existing lowfrequency resistance on virological response is controversial.Previous studies have shown an increased likelihood of virological response failure in patients with preexisting low-frequency resistance mutations after initiation of antiviral therapy,especially primary ART regimens containing non-nucleoside reverse transcriptase inhibitors(NNRTIs).[2]However,some studies have concluded differently,suggesting that pre-existing lowfrequency resistance mutations do not correlate with viral response failure.[3]This may be related to the method of detection of pre-existing low-frequency resistance mutations.

关 键 词：PATIENTS resistance REGIMEN 

分 类 号：R512.91[医药卫生—内科学]